Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017)

Paz-Ares Luis

首页> 外文期刊>Journal of Clinical Oncology >Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017)

【24h】

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017)

机译：III阶段随机试验的结果onartuzumab加尔洛替尼对orlotinib在先前治疗IIIB或IV非小细胞肺癌中的欧洲毒素：Metlung（Vol 35，PG 412,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Clinical Oncology》 |2018年第8期|共1页
作者
Paz-Ares Luis;
展开▼
作者单位

Univ Seville Seville Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017) [J] . Paz-Ares Luis Journal of Clinical Oncology . 2018,第8期

机译：III阶段随机试验的结果onartuzumab加尔洛替尼对orlotinib在先前治疗IIIB或IV非小细胞肺癌中的欧洲毒素：Metlung（Vol 35，PG 412,2017）
2. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer [J] . Spigel David R., Edelman Martin J., Mok Tony, Clinical lung cancer . 2012,第6期

机译：MetLung试验的治疗原理研究设计：Onartuzumab（MetMAb）联合厄洛替尼与单独使用厄洛替尼的随机，双盲III期研究在已接受IIIB或IV期Met阳性非小细胞化疗的患者中肺癌
3. MS 17.04 MET-Lung: A Phase III Trial of Onartuzumab (METMab) Plus Erlotinib vs Erlotinib in Previously Treated Stage IIIB or IV NSCLC [J] . K. Kelly Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：MES 17.04 MET-LUNG：在先前处理的阶段IIIB或IV NSCLC中，ONARTUZUMAB（METMAB）的III阶段试验（METMAB）加尔特替尼对erlotinib
4. PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS [C] . Jun Adachi, Yuichi Abe, Maiko Nagano, International Mass Spectrometry Conference . 2018

机译：用厄洛替尼处理的非小细胞肺癌细胞的磷脂蛋白酶揭示了耐药象征和潜在目标
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. A phase III randomized open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer [O] . R J Kelly, F A Shepherd, A Krivoshik, -1

机译：晚期IIIB / IV期非小细胞肺癌患者中ASP8273与厄洛替尼或吉非替尼的III期随机开放标签研究
7. Results from the phase iii randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage iiib or iv non–small-cell lung cancer: METLung [O] . Spigel David R., Edelman Martin J., OByrne Kenneth J., 2017

机译：厄那妥珠单抗联合厄洛替尼与厄洛替尼在先前治疗过的iiib或iv期非小细胞肺癌的iii期随机试验中的结果：METLung

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017)

著录项

相似文献

相关主题

期刊订阅